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Background: We sought to estimate the prevalence and incidence of hepatitis C virus (HCV) infection among Aboriginal 
young people who use drugs and to identify risk factors associated with HCV infection in this population.
Methods: The Cedar Project is a longitudinal study involving Aboriginal young people living in Vancouver and Prince 
George, British Columbia. Eligibility criteria include age from 14 to 30 years and self-reported use (smoking or injection) of 
illicit drugs (e.g., crystal methamphetamine, crack cocaine, heroin or other opiates, and cocaine) at least once in the month 
before enrolment. At each visit, participants completed a detailed questionnaire administered by an Aboriginal interviewer. 
For this analysis, we included information for 512 participants who were recruited between September 2003 and April 2005.
Results: Among the 512 participants, the prevalence of HCV infection was 34.8% (95% confidence interval [CI] 30.6%–
38.9%); the rates were similar in Prince George and Vancouver (34.5% and 35.0% respectively, p = 0.37). Among those who 
reported the use of injection drugs at baseline (n = 286), the prevalence of HCV infection was 59.4% (95% CI 53.8%–65.1%); 
the rate in this group was slightly higher in Prince George than in Vancouver (62.4% v. 57.1% respectively, p = 0.37). The 
prevalence was 3.5% among participants who reported smoking drugs (n = 226). In the multivariate logistic regression 
analysis, factors significantly associated with HCV infection among participants who used injection drugs included daily 
injection of opiates (adjusted odds ratio [OR] 2.7, 95% CI 1.0–7.4), reuse of syringes (adjusted OR 2.4, 95% CI 1.3–4.4), hav-
ing at least 1 parent who attended residential school (adjusted OR 1.9, 95% CI 1.1–3.4), female sex (adjusted OR 1.9, 95% CI 
1.1–3.4) and duration of injection drug use (per year) (adjusted OR 1.4, 95% CI 1.3–1.5). The crude incidence rate of HCV 
infection was 10.6% and the incidence density estimate was 9.9 per 100 person-years in this cohort.   
Interpretation: The prevalence of HCV infection was elevated among Aboriginal young people living in Prince George 
and Vancouver who use drugs. Culturally based prevention, treatment and harm-reduction programs are urgently needed 
in this population.
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ittle  is  known  about  the  extent  of  the 
hepatitis  C  (HCV)  epidemic  among  Aboriginal 
people in North America.1,2 In Canada, the reasons 
for this include limited surveillance data, underreporting 
of  HCV  infection  and  inconsistent  documentation  of 
ethnicity between the provinces.3 As a result, national 
surveillance data can offer only a minimum estimate of 
the  number  of  infected  people.  Regrettably,  alarming 
trends have already emerged. The Public Health Agency 
of Canada estimates that the prevalence of HCV infec-
tion is 0.8% in the general population of Canada and that 
it is 7-fold higher among Aboriginal people than among 
non-Aboriginal people.3 Estimates also suggest that the 
number of new cases is 2.5 times higher among Aborig-
inal people than in the general population.4 These data, 
however, represent Aboriginal people who live in urban 
areas and may not be generalizable to the entire Aborig-
inal population. A recent analysis conducted by Health 
Canada’s  First  Nations,  Inuit  and  Aboriginal  Health 
Branch found that Status Indians represented 4% of the 
population of the province of British Columbia but ac-
counted for 10% of cases of HCV infection reported in 
2001.4 Other data indicate that the prevalence of HCV 
infection in Aboriginal populations in different regions 
of Canada ranges between 0.4% and 29.3%.1
Indigenous  people’s  vulnerability  to  HCV  infection 
and other infectious diseases is becoming increasingly 
apparent worldwide. A better understanding of the fac-
tors and processes that cause drug-related harm among 
Aboriginal young people is urgently required. Aboriginal 
scholars have long suggested that any discussions relat-
ed to addictions and concomitant vulnerability to infec-
tious disease must be framed within the context of the 
legacy of colonization, including the residential school 
system, which removed more than 100 000 Aboriginal 
children from their families between 1874 and 19865–7 in 
an attempt to assimilate and Christianize the youngest 
generations of Aboriginal people in the absence of their 
parents and leaders.8 Although some factors unique to 
the  transmission  of  infectious  disease  among  young 
people who use injection drugs are known, studies ad-
dressing sex- and drug-related harm and the impact of 
the residential school system among Aboriginal young 
people are lacking, particularly in smaller cities and in 
reserve communities.9
Aboriginal leaders and HIV/AIDS service providers 
are concerned about the impact of the HIV and HCV epi-
demics, not only in small and large cities but in rural set-
tings as well.10 We conducted this study to estimate the 
prevalence and incidence of HCV infection among Ab-
original young people who use drugs and reside in Prince 
George, a forestry and mining town in the northern in-
terior of British Columbia, and in Vancouver. In addition, 
we sought to identify demographic and behavioural fac-
tors associated with HCV infection in this population.
Methods
Study  design  and  population.  We  followed  the 
guidelines provided in the Canadian Tri-Council Policy 
Statement: Ethical Conduct for Research Involving Hu-
mans11 in the development and conduct of this study. We 
paid particular attention to section 6.0, which pertains 
to  research  involving  Aboriginal  subjects.  Our  First 
Nations  collaborators,  including  Aboriginal  HIV/AIDS 
service organizations, were involved in the conception, 
design and implementation of the Cedar Project. They 
also reviewed the results of this analysis and approved 
this manuscript for publication. The study design was 
approved by the University of British Columbia/Provi-
dence Health Care Research Ethics Board. 
The Cedar Project is an ongoing prospective cohort 
study involving Aboriginal young people who use drugs 
and live in Prince George and Vancouver, with target re-
cruitments of 300 participants in each city. Eligibility 
criteria include age from 14 to 30 years and use (smok-
ing or injection) of illicit drugs (e.g., crystal metham-
phetamine, crack cocaine, heroin or other opiates, and 
cocaine)  in  the  month  before  enrolment.  Participants 
were eligible to participate if they had been residing in 
the greater Vancouver or Prince George regions and pro-
vided  written  informed  consent.  Nonrandom  samples 
of participants were recruited from both cities through 
a variety of methods, including referral by health care 
providers, community outreach, participant referral and 
word of mouth. Based on 2001 Census data, there are 
an estimated 14 080 Aboriginal people between 15 and 
34 years of age residing in the Northern Health Author-
ity (Prince George) and 7675 in the Vancouver Coastal 
Health Authority (Vancouver).
Data collection and laboratory testing. All partici-
pants met with a single study coordinator, who explained 
procedures,  sought  informed  consent  and  confirmed 
study eligibility. Venous blood samples were drawn and 
tested for HIV and HCV antibodies. At enrolment, par-
ticipants completed an interviewer-administered ques-
tionnaire to elicit sociodemographic data and data on 
their use (smoking or injection) of illicit drugs, injection 
practices, sexual risk behaviours and use of health care 
services.  Various  sections  of  the  Vancouver  Injection 
Drug  User  Study  (VIDUS)  questionnaire  were  tested 
and included in our baseline questionnaire.12 Aboriginal 
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viewers were blinded to the HIV and HCV status of the 
participants.
We used algorithms for HCV serologic testing similar 
to those used in other studies conducted in this region.13 
In  brief,  AxSYM  HCV  version  3.0  (Abbott  Laborator-
ies, Chicago, Ill.) was used to screen all plasma samples. 
Negative samples did not undergo further testing. All 
positive  samples  underwent  further  testing  with  the 
recombinant Ortho HCV 3.0 ELISA test system (Ortho 
Clinical Diagnostic Inc., Rochester, NY). Samples that 
tested positive with both assays were classified as posi-
tive. Samples that tested positive by the AxSYM HCV 
test and negative by the Ortho HCV test were classified 
as negative. 
All eligible participants had private interviews, includ-
ing pre- and post-test counselling with trained nurses. 
Participants were requested to return for their HCV test 
result, at which time referral for HIV/AIDS and hepatitis 
C care was provided if requested. In addition, subjects 
were referred to clinics for immunization against hepatitis 
A and B. 
Participants were given a small stipend at each study 
visit  as  compensation  for  their  time  and  to  facilitate 
transportation.
Estimation  of  HCV  prevalence  and  incidence. 
To estimate the prevalence of HCV infection, we used a 
cohort of 512 participants who were recruited between 
September 2003 and April 2005, had completed their 
baseline interview during this period and had an HCV 
antibody test result from this visit. 
To estimate the incidence of HCV infection, we used 
a cohort of 198 participants who completed their enrol-
ment visit between September 2003 and October 2004, 
were HCV-negative at enrolment and completed at least 
1 follow-up HCV antibody test during the observation 
period  (September  2003  to  April  2005).  The  event  of 
interest in this analysis was time to HCV infection. For 
participants with new infection, we calculated time to 
HCV infection as the duration (in months) from the date 
of enrolment to the date of the first positive antibody test 
result.  Follow-up  time  for  event-free  participants  was 
calculated as the duration from enrolment to the date of 
their most recent negative antibody test result. We deter-
mined estimates of HCV incidence using crude rates and 
incidence density methods. To assess the strength of as-
sociation between factors of interest and HCV infection, 
we calculated both unadjusted and adjusted odds ratios 
(ORs) and 95% confidence intervals (CIs). The low num-
ber of HCV seroconversions (n = 21) during the study 
period did not permit a thorough analysis of risk factors 
for incident infection.
Because of the known association between HCV in-
fection and parenteral drug use, we stratified prevalence 
rates  of  HCV  infection  by  injection  and  noninjection 
drug use. We restricted analyses of risk factors to par-
ticipants who reported injection of drugs. Variables of 
interest included age, incarceration and housing (stable 
v. unstable). Participants considered to have stable hous-
ing were those living in their own house or apartment. 
Unstable  housing  was  defined  as  living  arrangements 
that included single-room occupancy hotels, transitional 
living  arrangements  (“couch  surfing”)  and  homeless-
ness. Risky injection practices included borrowing and 
lending  of  previously  used  syringes.  Drug  use  behav-
iours included frequent injection, type of drug, binge-
ing behaviour and overdose experience. As in previous 
reports,  we  defined  frequent  injection  as  injection  of 
cocaine, heroin or “speedballs” (cocaine and heroin com-
bined)  once  or  more  per  day.  We  defined  bingeing  as 
periods when drugs were injected more frequently than 
usual. Risky sexual behaviours in the 6 months before 
enrolment and in the 6 months before each follow-up 
visit  included  having  an  HCV-positive  sexual  partner 
and exchanging money or drugs for sex.
Statistical analysis. We analyzed bivariate categor-
ical data using the Pearson χ2 test. We used the Fisher 
exact  test  to  analyze  bivariate  categorical  data  when 
25% or more of the expected cell frequencies in a con-
tingency table were less than 5. We compared numeric 
variables (e.g., age at enrolment, age at first injection) 
between  HCV-positive  and  HCV-negative  participants 
using the Wilcoxon rank-sum test. We used multivari-
ate logistic regression analysis to model the independent 
association  of  demographic  variables  and  behavioural 
risk factors with HCV infection. Variables that were at 
least marginally significant in unadjusted analyses (p < 
0.10) were included in the multivariate logistic regres-
sion model. We calculated unadjusted ORs and 95% CIs 
using logistic regression analysis. All reported p values 
are 2-sided.
results
The  demographic  characteristics  of  the  512  partici-
pants are summarized in Table 1. A total of 178 partici-
pants were HCV positive at enrolment, for a prevalence 
of 34.8% (95% CI 30.6%–38.9%). The prevalence was 
similar in both locations (34.5% in Prince George and 
35.0% in Vancouver, p = 0.37). Of the 286 participants 
at  baseline  who  reported  using  injection  drugs,  170 
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53.8%–65.1%); 38% of these HCV-positive participants 
reported that they had been injecting drugs for 2 years 
or less. The prevalence among those who used injection 
drugs was higher in Prince George than in Vancouver 
(62.4% v. 57.1%); this difference was not statistically 
significant (p = 0.37). The prevalence among the 226 
participants at baseline who reported noninjection use 
of drugs was 3.5%.
A total of 199 participants who were HCV negative 
at enrolment were followed for a median of 11 months. 
These participants contributed 212.7 person-years of ob-
servation (data not shown). During the observation per-
iod, 21 new infections were recorded in this cohort, for a 
crude incidence rate of 10.6% and an incidence density 
estimate of 9.9 per 100 person-years. The incidence of 
HCV infection was higher in Prince George than in Van-
couver (12.9 v. 7.5 per 100 person-years); this difference 
was not statistically significant (p > 0.10). The incidence 
density was 22.6 per 100 person-years among the par-
ticipants who reported injection drug use (n = 71) and 
6.7 per 100 person-years among those who reported non-
injection drug use (n = 128). Of the 21 participants with 
new HCV infection, 14 (67%) reported use of injection 
drugs at enrolment. Of the 7 (33%) who reported non-
injection drug use at enrolment, all 7 reported use of in-
jection drugs at 1 or more follow-up visits.
In the univariate analysis, we found that 
HCV  infection  at  enrolment  among  the 
participants who reported use of injection 
drugs  was  significantly  associated  with 
daily  injection  of  drugs  (Table  2):  speed-
balls (unadjusted OR 5.6, 95% CI 1.6–19.3), 
morphine (unadjusted OR 3.7, 95% CI 1.0–
12.9), cocaine (unadjusted OR 3.3, 95% CI 
1.8–6.1),  hydromorphone  (unadjusted  OR 
3.1, 95% CI 0.9–11.2) and heroin (unadjust-
ed OR 2.0, 95% CI 1.1–3.5). HCV infection at 
enrolment was also significantly associated 
with  female  sex,  having  at  least  1  parent 
who  attended  residential  school,  involve-
ment  in  sex  work,  incarceration,  current 
or past methadone treatment and reuse of 
syringes. Other significant risk factors were 
duration of drug use and age (Table 2): par-
ticipants who were HCV positive at enrol-
ment reported significantly longer periods 
of  drug  use  (injection  drugs,  unadjusted 
OR 1.42 [95% CI 1.26–1.56]; noninjection 
drugs, unadjusted OR 1.12 [95% CI 1.05–
1.20) and were older (unadjusted OR 1.11, 
95% CI 1.03–1.18) than the HCV-negative participants.
In the multivariate analysis, we combined responses 
for daily use of some opiates (morphine, hydromorph-
one or speedballs) into 1 variable (i.e., daily injection of 
opiates) because the numbers were small for both HCV-
positive and HCV-negative participants. We found that 
the following risk factors were independently associated 
with HCV infection in the multivariate analysis: daily 
injection of opiates (adjusted OR 2.7, 95% CI 1.0–7.4), 
reuse of syringes (adjusted OR 2.4, 95% CI 1.3–4.4), hav-
ing at least 1 parent who attended residential school (ad-
justed OR 1.9, 95% CI 1.1–3.4), female sex (adjusted OR 
1.9, 95% CI 1.1–3.4) and duration of injection drug use 
(adjusted OR 1.4, 95% CI 1.3–1.5) (Table 3). Estimates 
of risk for the variables in this multivariate model were 
similar after adjustment for geographic location.
Interpretation
In this group of Aboriginal young people who use injec-
tion drugs in Prince George and Vancouver, HCV infec-
tion spread to levels above 55%, and the incidence rate of 
HCV infection was 10.6%. These findings were unexpect-
ed and reflect how rapidly this virus can spread even in 
the early period just after injection drug use begins.13–16 
Aboriginal and non-Aboriginal scholars agree that the 
relation between the cumulative effects of historical and 
current trauma are directly related to the HIV epidemic 
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Table 1: Demographic characteristics of 512 Aboriginal young people who 
participated in the Cedar Project between September 2003 and April 2005
No. (%) of participants*
Characteristic n = 512
Female sex 265 (51.8)
Age at enrolment, yr, median (range) 23 (14–30)
Heterosexual social/sexual identity 456 (89.1)
Single marital status 390 (76.2)
High school not completed 423 (82.6)
Unstable housing 230 (44.9)
≥ 1 parent attended residential school 286 (55.9)
Taken from biological parents (ever) 327 (63.9)
Age when ‰  rst taken from biological parents, yr, median (range) 5 (1–19)
Nonconsensual sex (ever) 244 (47.7)
Age at ‰  rst nonconsensual sex, yr, median (range) 7 (1–25)
Attempted suicide (ever) 187 (36.5)
Incarcerated (ever) 342 (66.8)
Age at ‰  rst incarceration, yr, median (range) 16 (10–28)
Pregnancy (ever) among female participants 201 (39.3)
Involvement in survival sex work† (ever) 195 (38.1)
Age at ‰  rst involvement in survival sex work, yr, median (range) 16 (10–28)
Injection drug use 286 (55.9)
*Unless stated otherwise.
†Exchanging sex for such things as food and shelter.
†Exchanging sex for such things as food and shelter.among indigenous peoples in North America. The preva-
lence  of  HCV  infection  among  the  Aboriginal  young 
people who reported use of injection drugs in our study 
(59%) was higher than the prevalence in a previous study 
involving young people who were using injection drugs 
in  Vancouver  (46%).17  Furthermore,  the  prevalence  of 
HCV  infection  among  the  Aboriginal  young  people  in 
our study who live in the northern community of Prince 
George  mirrored  the  prevalence  among  young  people 
using  injection  drugs  in  Vancouver’s  Downtown  East-
side.  Given  that  Vancouver  has  consistently  been  de-
scribed as an epicentre of the HIV and HCV epidemics in 
British Columbia and in Canada since the 1990s, these 
findings indicate that the faces of these epidemics are 
changing.
We found that daily injection of opiates, reuse of syr-
inges, having at least 1 parent who attended residential 
school, female sex and duration of injection drug use were 
independent risk factors for HCV infection at baseline. 
The strong association between frequent use of opiates 
and HCV prevalence is a relatively new finding in this 
setting. A persistent risk factor for blood-borne infection 
in Vancouver’s Downtown Eastside is frequent injection 
of cocaine.16,17 The fact that young people in our study 
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Table 2: Demographic and behavioural characteristics of HCV-positive and HCV-negative participants who reported use 
of injection drugs at enrolment
Variable
HCV status; % of participants* Unadjusted odds 
ratio (95% CI) HCV positive, % HCV negative, % p value
Age, yr, median (IQR) 25 (14–30) 24 (15–30)     0.004   1.11 (1.03–1.18)
Female sex 62.4 47.4 0.012 1.9 (1.1–3.0)
Living in Prince George 45.9 40.5 0.369 1.2 (0.8–2.0)
Completed high school or attended technical school, college or university 19.1 16.5 0.587 1.2 (0.6–2.2)
Unstable housing 51.9 57.7 0.344 0.8 (0.5–1.2)
≥ 1 parent attended residential school 62.4 50.0 0.038 1.7 (1.0–2.7)
Taken from biological parents (ever) 62.4 63.8 0.804 0.9 (0.6–1.5)
Sexual behaviour
Nonconsensual sex (ever) 54.1 54.3 0.974 1.0 (0.6–1.6)
Sex with client in previous 6 mo 44.7 26.7 0.002 2.2 (1.3–3.7)
Paid for sex (ever) 57.1 39.7 0.004 2.0 (1.3–3.3)
Attempted suicide 37.7 43.1 0.355 0.8 (0.5–1.3)
Detained by police 83.5 78.5 0.278 1.4 (0.8–2.5)
Incarcerated (ever) 81.2 69.8 0.026 1.9 (1.1–3.2)
Enrolment in alcohol or drug treatment program (ever) 80.6 71.6 0.075 1.7 (0.9–2.8)
Methadone treatment program (ever) 35.9 12.1 < 0.001 4.1 (2.1–7.7)
Methadone treatment program (current) 14.1 4.3 0.007 3.6 (1.4–9.9)
Daily drug use (≥ 1 injections per day)
Speedballs† 13.0 2.6 0.002 5.6 (1.6–19.3)
Morphine 8.8 2.6 0.033 3.7 (1.0–12.9)
Cocaine 36.5 14.7 < 0.001 3.3 (1.8–6.1)
Hydromorphone 7.6 2.6 0.068 3.1 (0.9–11.2)
Heroin 32.9 19.8 0.015 2.0 (1.1–3.5)
Crystal methamphetamine 6.1 7.6 0.655 0.8 (0.3–2.1)
Reuse of syringes 41.2 21.5 < 0.001 2.5 (1.5–4.4)
Borrowing of injection equipment 20.0 12.9 0.119 1.7 (0.9–3.3)
DiŸ   culty accessing clean needles 15.5 11.1 0.355 1.5 (0.6–3.4)
Binge drug use 20.0 16.4 0.439 1.3 (0.7–2.4)
Help required to inject drugs 27.1 36.2 0.100 0.7 (0.4–1.1)
Duration of drug use, yr, median (IQR)
Injection drugs 5 (< 1–15) 1 (< 1–10) < 0.001 1.42 (1.26–1.56)
Noninjection drugs 7 (< 1–17) 4 (< 1–15) < 0.001 1.12 (1.05–1.20)
Note: CI = con‰  dence interval, HCV = hepatitis C virus, IQR = interquartile range.
*Unless stated otherwise.
†Cocaine and heroin combined.reported  injecting  a  wide  array  of  opiates  (morphine, 
hydromorphone and speedballs) along with cocaine on 
a daily basis and that daily opiate use, and not cocaine 
use, was associated with HCV seropositivity warrants 
further investigation. Methadone maintenance therapy 
is the primary treatment of opiate addiction in Canada 
and has proven effective in preventing HIV infection.18 
Unfortunately, the evidence supporting its effectiveness 
in reducing HCV incidence is less substantial.19,20 In this 
study, methadone maintenance therapy was not associ-
ated with a reduction of risk for HCV infection. Despite 
this lack of evidence, methadone maintenance therapy 
continues to be recommended, in part because it helps 
to reduce the number of daily opiate injections and be-
cause injection episodes are presumed to be safer when 
they occur. Increased efforts must be made to determine 
the barriers to receiving such treatment for Aboriginal 
young people, particularly in smaller city centres.
We found that reusing injection equipment was an-
other  significant  risk  factor  for  HCV  infection  in  our 
study. Because of previously demonstrated associations 
between  other  high-risk  behaviours  related  to  access-
ibility of clean syringes,18 we compared participants in 
our study who reported reusing syringes during the 6 
months before enrolment with those who did not reuse 
injection equipment. Indeed, participants who reported 
reusing  their  syringes  were  significantly  more  likely 
to report borrowing and sharing injection equipment, 
bingeing with injection drugs and requiring assistance 
injecting during that period. 
In recent years the federal government and Aborig-
inal communities across Canada have been debating the 
relative toll of the cumulative and intergenerational ef-
fects of historical trauma related to the Indian residen-
tial school system.19 The forced removal of children from 
their homes and placement in boarding schools is con-
sidered by many researchers, based on testimony given 
by  family  and  community,  to  be  directly  responsible 
for  poor  health  outcomes  among  survivors,  including 
the abuse of drugs and alcohol.20 Cur-
rently, there are an estimated 80 000 
survivors of the residential school sys-
tem alive in Canada, of whom 35 000 
are in British Columbia.21 As affected 
communities raise their children and 
grandchildren,  the  intergenerational 
effects of abuse and familial fragmen-
tation become evident.22,23 Several Ab-
original  HIV/AIDS  service  providers 
have suggested that drug use is just one 
way that people deal with the complex effects of poverty, 
despair, discrimination, loss of language and traditional 
territories and the erosion of culture.24 Previous research 
has identified a bivariate relation between having a par-
ent who attended residential school and involvement in 
the child welfare system with sexual abuse among Ab-
original young people who use drugs in British Colum-
bia.25 The mechanism of effect between having a parent 
who attended residential school  and increased risk of 
HCV infection should be the subject of further study.
We  found  that  female  sex  was  significantly  associ-
ated  with  HCV  infection,  even  after  we  adjusted  for 
demographic and behavioural risk factors. Although the 
majority of these infections can be attributed to injec-
tion-related  risk  behaviours,  many  young  Aboriginal 
women are intimately involved with men who are usu-
ally older and who use injection drugs themselves.26,27 
Indeed, research has demonstrated that, for women who 
rely on their partners for drug acquisition, preparation 
and injection, the distribution of power and control in 
sexual and injection relationships often lies with drug-
injecting men who control the money and the drugs.28,29 
Combined, these factors lead to an increased likelihood 
of unsafe sex and of the female partner being “second on 
the needle.”12
Our study has several limitations. We used self-reported 
behavioural data obtained from a non-probability sample 
of individuals. Consequently, there is potential for recall 
bias, socially desirable reporting and misclassification of   
exposure  variables.  Responses  to  questions  concerning 
drug  use  and  sexual  behaviours  may  have  been  influ-
enced by the participants’ knowledge of their HCV anti-
body status. In addition, recall problems may exist with 
reporting of past traumatic life events (e.g., being taken 
from biological parents, whether parents attended residen-
tial school, and sexual abuse or nonconsensual sex). The 
effect of memory on our estimates of risk for these factors 
is difficult to assess. Non  differential misclassification of 
an exposure variable and the resultant bias can lead to a 
Table 3: Factors independently associated with HCV infection among participants 
who reported use of injection drugs
Risk factor Adjusted odds ratio (95% CI)* 
Daily injection of opiates (speedballs, morphine or dilaudid) 2.7 (1.0–7.4)
Reuse of syringes 2.4 (1.3–4.4)
≥ 1 parent attended residential school 1.9 (1.1–3.4)
Female sex 1.9 (1.1–3.4)
Duration of injection drug use (per year) 1.4 (1.3–1.5)
Note: HCV = hepatitis C virus, CI = con‰  dence interval.
*Adjusted for enrolment in methadone treatment program (ever and current), daily injection of cocaine, 
sex with client in previous 6 months, paid for sex (ever), daily injection of heroin and incarceration (ever).
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from the null hypothesis.30 Furthermore, our estimate of 
the incidence of HCV infection may have been affected 
by differential drop-out. We found that participants who 
were lost to follow-up were younger and more frequent 
drug users than those who completed follow-up visits. 
Therefore, our estimates of incidence may be lower than 
their true values.
Despite these limitations, we believe these data pro-
vide  important  epidemiologic  information  about  the 
prevalence and incidence of HCV infection in a high-risk 
Aboriginal population. In the absence of postexposure 
prophylaxis for HCV infection and an effective vaccine 
against HCV, primary prevention programs must focus 
on safer injection practices and reducing the number of 
people who initiate injection drug use. The high baseline 
prevalence  rates  in  our  study  underscore  the  import-
ance of carefully examining the effectiveness of current 
harm reduction initiatives in both rural and urban set-
tings. Culturally based prevention, treatment and harm- 
reduction programs are urgently needed for young people 
who use injection drugs.  Acknowledging the intergener-
ational trauma related to the residential school system 
may be one way that Aboriginal leadership and addiction 
specialists can begin to mitigate the potential impact of 
the HCV epidemic in their communities.
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